drugset / Trial / NCT00974441

Divalproex Sodium 500 mg Extended Release Tablets Under Fasting Conditions

NCT00974441

Phase 1 Completed 48 enrolled Teva Pharmaceuticals USA
RandomizedCrossoverOpen-label

Summary

This study will compare the relative bioavailability (rate and extent of absorption) of 500 mg Divalproex Sodium (equivalent to 500 mg Valproic Acid) Extended Release Tablets with that of Depakote® ER Tablets following a single oral dose (1 x 500 mg tablet) in healthy adult subjects administered under fasting conditions.

Timeline

Start
2006-08
Primary completion
2006-09
Completion
2006-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Divalproex Sodium Small molecule 500 mg Oral

Indications

No indication recorded.